Shareholder Alert: The Ademi Firm Investigates Whether Walgreens Boots Alliance, Inc. is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Walgreens (NASDAQ: WBA) for possible breaches of fiduciary duty and other violations of law in its transaction with Sycamore.

Click here to learn how to join our investigation and obtain additional information or contact us at [e-mail] or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Walgreens stockholders will receive only $11.45 per share in cash at closing and one non-transferable right to receive up to $3.00 in cash per Walgreens share from the future monetization of Walgreen’s debt and equity interests in VillageMD, which includes the Village Medical, Summit Health and CityMD businesses. Walgreens insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Walgreens by imposing a significant penalty if Walgreens accepts a competing bid. We are investigating the conduct of the Walgreens board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.